Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
Journal of Managed Care & Specialty Pharmacy
|
September 26, 2025
Clinical and economic impact of recurrence in unresected non-small cell lung cancer treated with primary stereotactic body radiotherapy: A real-world study using SEER-Medicare data
Pragya Rai, Andrew Song, Su Zhang, et al.
The Journal of Biological Chemistry
|
September 10, 2010
Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity
Haijuan Wang, Michael P Holloway, Li Ma, et al.
Journal of Clinical Medicine
|
December 11, 2025
Real-World Clinical Outcomes and Biopsy Patterns of Older Patients with Unresected Non-Small-Cell Lung Cancer Treated with Primary Stereotactic Body Radiotherapy
Pragya Rai, Su Zhang, Yan Song, et al.
Investigational New Drugs
|
June 22, 2020
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)
Toshihiko Doi, Yutaka Fujiwara, Kohei Shitara, et al.
BMC Cancer
|
July 25, 2024
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study
Michael Boyer, Rina Hui, Damien Urban, et al.
BMC Cancer
|
July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study
Takaaki Tokito, Oleksii Kolesnik, Jens Sørensen, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
Aaron S Mansfield, Roy S Herbst, Gilberto de Castro, et al.
The New England Journal of Medicine
|
June 5, 2023
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer
Heather Wakelee, Moishe Liberman, Terufumi Kato, et al.
The Lancet. Oncology
|
September 15, 2022
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Mary O'Brien, Luis Paz-Ares, Sandrine Marreaud, et al.
The Annals of Thoracic Surgery
|
November 7, 2025
Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671
Moishe Liberman, David R Jones, Heather Wakelee, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
Journal of Managed Care & Specialty Pharmacy
|
September 26, 2025
Clinical and economic impact of recurrence in unresected non-small cell lung cancer treated with primary stereotactic body radiotherapy: A real-world study using SEER-Medicare data
Pragya Rai, Andrew Song, Su Zhang, et al.
The Journal of Biological Chemistry
|
September 10, 2010
Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity
Haijuan Wang, Michael P Holloway, Li Ma, et al.
Journal of Clinical Medicine
|
December 11, 2025
Real-World Clinical Outcomes and Biopsy Patterns of Older Patients with Unresected Non-Small-Cell Lung Cancer Treated with Primary Stereotactic Body Radiotherapy
Pragya Rai, Su Zhang, Yan Song, et al.
Investigational New Drugs
|
June 22, 2020
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)
Toshihiko Doi, Yutaka Fujiwara, Kohei Shitara, et al.
BMC Cancer
|
July 25, 2024
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study
Michael Boyer, Rina Hui, Damien Urban, et al.
BMC Cancer
|
July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study
Takaaki Tokito, Oleksii Kolesnik, Jens Sørensen, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
Aaron S Mansfield, Roy S Herbst, Gilberto de Castro, et al.
The New England Journal of Medicine
|
June 5, 2023
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer
Heather Wakelee, Moishe Liberman, Terufumi Kato, et al.
The Lancet. Oncology
|
September 15, 2022
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Mary O'Brien, Luis Paz-Ares, Sandrine Marreaud, et al.
The Annals of Thoracic Surgery
|
November 7, 2025
Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671
Moishe Liberman, David R Jones, Heather Wakelee, et al.
Page
of 4